10:23

Lessons from HIV campaigns. Professor Mark Nelson

11:40

Diagnosing the undiagnosed and engaging the disengaged. Dr Andy Ustianowski

12:33

Charles Gore: Reflections on 18 years at the Hepatitis C Trust and the future for hepatitis C

15:49

LJWG pharmacy testing & treatment overview. Dr Suman Verma

10:16

The LJWG project on the importance of data processes in pathways. Dr Katherine Morely,

04:46

Hepatitis C, Action in London. Susan Hall

11:39

Economic evaluations of case finding for PWID who have hepatitis C. Professor Peter Vickerman

10:27

The changing landscape & the future of hepatitis C treatment. Janet Catt/Chris Laker

10:24

Addressing the health inequalities issue of hepatitis C in London.Dr Yvonne Doyle

05:40

LJWG Conference 2018. 7 years to HCV elimination: The road to 2025. Stuart Smith

04:06

The impact of hepatitis C

04:16

There's a footprint to leave: Hepatitis C elimination in London

03:54

Moving on with my life: Getting cured of hepatitis C

01:15:19

GFN Dialogues - Glasgow discussion

01:19:31

GFN Dialogues - Liverpool Discussion

01:09:10

GFN Dialogues - Leicester discussion

13:33

GFN Dialogues Glasgow, Robbie Preece

07:47

GFN Dialogue Glasgow - Dr Joanna Miler

10:09

GFN Dialogue Glasgow - Andy Morrison

03:42

GFN Dialogue Leicester - Alan Law

04:56

GFN Dialogue Leicester - Louise Ross

07:55

GFN Dialogue Leicester - Ruth Tennant

13:09

GFN Dialogue Leicester - Dr Konstantinos Farsalinos

11:44

Tobacco harm reduction roadshow - Leicester, Liverpool & Glasgow

41:40

Carl Hart - Hit Hot Topics 2016

14:20

Users of anabolic steroids and associated drugs. A sentinel population

16:58

Introducing multi-agency safety testing to the UK

16:12

The Global State of Harm Reduction 2016

22:56

Q&A Drugs & Race Session HIT Hot Topics 2016

17:44

Proportionate policing

11:25

Race and drugs, the French double blindness

14:39

From 'other' to 'us'.

16:49

Supervised injecting in Scotland? A travel fellowship experience.

17:17

Say why to drugs

18:44

Hearing from heroin users

20:01

Sex, drugs and the role of a consultant midwife

16:54

Mat Southwell - drug user organising and the work of EURONPUD

18:58

Problematising Hepatitis C Treatment Priorities in England

13:36

The Janus face of drug prohibition: which way are we heading?

15:50

GFN 2016: A Swedish perspective on snus

16:43

GFN 2016: The e-cigarette environment in Australia

19:17

GFN2016: E-cigarettes health potential: current evidence and future areas of exploration

08:11

GFN2016: 'Not Blowing Smoke' - the fight against misleading messages

07:11

GFN2016: Disharmony in the Implementation of the European TPD

14:05

GFN2016: Population impacts of snus - tobacco initiation & cessation

16:33

GFN2016: Lessons for vapers from drugs harm reduction and drug policy reform

21:29

GFN2016: What would good regulation of e-cigarettes look like?

24:44

GFN2016: Unacountable and non-transparent: is the FCTC a threat to public health?

12:08

GFN2016: Population impact of e-cigarettes: recent evidence from the UK

11:58

GFN2016: Asking the right questions about smoking and alternative nicotine delivery systems

14:19

GFN2016: Prices & e-cigarette demand in the EU

16:38

GFN2016: Perceptual and experiential factors in switching to e-cigarettes

21:10

GFN2016: Safety & toxicology of e-cigarettes

13:27

GFN2016: Exhaled aerosol particles e-cigs & cigarettes

09:06

GFN2016: What I've learned from GFN 2016 - Harry Shapiro

17:31

GFN2016: E-cigarettes: Gateway or Roadblock to Cigarette Smoking?

14:28

GFN2016: Research on electronic cigarettes in Poland

17:38

GFN2016: Tobacco Heating System (THS) 2.2 cardiovascular disease risk assessment

15:55

GFN2016: Compensatory puffing behaviours in e-cigarette users

12:43

GFN2016: The power of non-nicotine factors in the habitual use of nicotine products